Search

Search Constraints

You searched for: Author/Creator Garufi, Carlo

Search Results

1. A 15-year experience of two hundred and twenty five consecutive right hepatectomies. Issue 1 (January 2017)

2. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Issue 2 (1st February 2019)

3. Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study. (22nd February 2019)

4. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting. Issue 7 (7th August 2019)

5. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial. Issue 10 (10th December 2020)

6. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Issue 14 (30th April 2013)

7. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Issue 14 (30th April 2013)

8. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence. Issue 11 (15th January 2020)

10. Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. (22nd April 2020)